buyModerate
Marcus Lemonis bought $1000k of NXH
EXECUTIVE CHAIRMAN OF BOARD at BED BATH & BEYOND, INC.. 156,985 shares at an average of $6.37, traded Oct 27, 2024, filed Oct 28, 2024.
Conviction score
55Value
$1000k
156,985 shares
Holdings after
365,530
+75% from before
From 52-week low
-
no price yet
From 52-week high
-
no price yet
Score components
- +20RoleChair
- +25Trade size$1000k at market
- +10Relative to holdingsHoldings up 75%
- 0Price contextNo price history yet
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Rows in this filing
Every transaction in Form 4 0001415889-24-025662, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 27, 2024 | POpen-market purchase Common Stock | +156,985 | $6.37 | $1000k | 365,530 | Oct 28, 2024 |
Related signals
Other insiders at BED BATH & BEYOND, INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 65Notable | NXHbuy BED BATH & BEYOND, INC. | Marcus Lemonis EXECUTIVE CHAIRMAN & CEO | $1.0M 362,319 shares | +51% | |
| 35Weak | NXHbuy BED BATH & BEYOND, INC. | Marcus Lemonis EXECUTIVE CHAIRMAN & CEO | $101k 21,691 shares | +3% | |
| 36Weak | NXHbuy BED BATH & BEYOND, INC. | Joseph J Tabacco Jr director | $102k 20,000 shares | +14% | |
| 2Weak | BED BATH & BEYOND, INC. | Adrianne Lee President & CFO | $22k 2,200 shares | -4% | |
| 30Weak | NXHbuy BED BATH & BEYOND, INC. | Marcus Lemonis EXECUTIVE CHAIRMAN OF BOARD | $97k 19,193 shares | +4% | |
| 46Moderate | NXHbuy BED BATH & BEYOND, INC. | Marcus Lemonis EXECUTIVE CHAIRMAN OF BOARD | $500k 71,428 shares | +20% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.